New hope for japanese patients battling Tough-to-Treat blood cancer
NCT ID NCT04773522
Summary
This study tested the safety of an experimental drug called talquetamab in 15 Japanese patients with multiple myeloma that had returned or stopped responding to standard treatments. The main goal was to see how well patients tolerated the drug at a specific dose level. Researchers monitored for side effects while also checking if the drug showed any signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Iwate Medical University Hospital
Shiwa-gun, 028-3695, Japan
-
Japanese Red Cross Medical Center
Shibuya City, 150-8935, Japan
-
Nagoya City University Hospital
Nagoya, 467 8602, Japan
-
National Cancer Center Hospital East
Kashiwa, 277 8577, Japan
-
National Hospital Organization Okayama Medical Center
Okayama, 701-1192, Japan
-
Shonan Kamakura General Hospital
Kamakura-shi, 247-8533, Japan
Conditions
Explore the condition pages connected to this study.